FDA
-
-
-
-
-
-
-
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
-
-
-
-
-
-
-
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
-
-
-
-
-
334,274 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


